PMID- 23495730 OWN - NLM STAT- MEDLINE DCOM- 20140206 LR - 20231104 IS - 1349-7006 (Electronic) IS - 1347-9032 (Print) IS - 1347-9032 (Linking) VI - 104 IP - 7 DP - 2013 Jul TI - The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect. PG - 779-89 LID - 10.1111/cas.12152 [doi] AB - This review focuses primarily on my own research, including pathogenic mechanisms of microbial infection, vascular permeability in infection and tumors, and effects of nitric oxide (NO), superoxide anion radical (O(2)(-)), and 8-nitroguanosine in the enhanced permeability and retention (EPR) effect for the tumor-selective delivery of macromolecular agents (nanomedicines). Infection-induced vascular permeability is mediated by activation of the kinin-generating protease cascade (kallikrein-kinin) triggered by exogenous microbial proteases. A similar mechanism operates in cancer tissues and in carcinomatosis of the pleural and peritoneal cavities. Infection also stimulates O(2)(-) generation via activation of xanthine oxidase while generating NO by inducing NO synthase. These chemicals function in mutation and carcinogenesis and promote inflammation, in which peroxynitrite (a product of O(2)(-) and NO) activates MMP, damages DNA and RNA, and regenerates 8-nitroguanosine and 8-oxoguanosine. We showed vascular permeability by using macromolecular drugs, which are not simply extravasated through the vascular wall into the tumor interstitium but remain there for prolonged periods. We thus discovered the EPR effect, which led to the rational development of tumor-selective delivery of polymer conjugates, micellar and liposomal drugs, and genes. Our styrene-maleic acid copolymer conjugated with neocarzinostatin was the first agent of its kind used to treat hepatoma. The EPR effect occurs not only because of defective vascular architecture but also through the generation of various vascular mediators such as kinin, NO, and vascular endothelial growth factor. Although most solid tumors, including human tumors, show the EPR effect, heterogeneity of tumor tissue may impede drug delivery. This review describes the barriers and countermeasures for improved drug delivery to tumors by using nanomedicines. CI - (c) 2013 Japanese Cancer Association. FAU - Maeda, Hiroshi AU - Maeda H AD - Institute of Drug Delivery System Research, Sojo University, Kumamoto, Japan. hirmaeda@ph.sojo-u.ac.jp LA - eng PT - Journal Article PT - Review DEP - 20130422 PL - England TA - Cancer Sci JT - Cancer science JID - 101168776 RN - 0 (8-nitroguanosine) RN - 0 (Antineoplastic Agents) RN - 0 (Free Radicals) RN - 0 (Nitro Compounds) RN - 12133JR80S (Guanosine) RN - 31C4KY9ESH (Nitric Oxide) SB - IM MH - Animals MH - Antineoplastic Agents/pharmacology MH - Capillary Permeability/drug effects MH - Free Radicals/*metabolism MH - Guanosine/analogs & derivatives/pharmacology MH - Humans MH - Infections/metabolism/*microbiology MH - Nanomedicine/methods MH - Neoplasms/*blood supply/drug therapy/metabolism/*microbiology MH - Nitric Oxide/pharmacology MH - Nitro Compounds/pharmacology PMC - PMC7657157 EDAT- 2013/03/19 06:00 MHDA- 2014/02/07 06:00 PMCR- 2013/07/01 CRDT- 2013/03/19 06:00 PHST- 2013/03/01 00:00 [received] PHST- 2013/03/10 00:00 [accepted] PHST- 2013/03/19 06:00 [entrez] PHST- 2013/03/19 06:00 [pubmed] PHST- 2014/02/07 06:00 [medline] PHST- 2013/07/01 00:00 [pmc-release] AID - CAS12152 [pii] AID - 10.1111/cas.12152 [doi] PST - ppublish SO - Cancer Sci. 2013 Jul;104(7):779-89. doi: 10.1111/cas.12152. Epub 2013 Apr 22.